STOCK TITAN

United Therapeutics Corp - UTHR STOCK NEWS

Welcome to our dedicated news page for United Therapeutics (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect United Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of United Therapeutics's position in the market.

Rhea-AI Summary
United Therapeutics (Nasdaq: UTHR) achieved a groundbreaking milestone by successfully conducting the world's first xenothymokidney transplant into a living recipient. The transplant combined a genetically modified pig's kidney and thymus tissue to condition the recipient's immune system and reduce rejection risk. This historic achievement follows previous successful UHeart transplants and demonstrates the potential of xenotransplantation to address the organ shortage crisis. The transplant was authorized by the FDA and performed by surgeons at NYU Langone Health, marking a significant advancement in medical science and offering hope to patients awaiting organ transplants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
Rhea-AI Summary
United Therapeutics (Nasdaq: UTHR) will report its Q1 2024 financial results on May 1, 2024. The company will host a webcast accessible via their website. United Therapeutics is a public benefit focusing on novel pharmaceutical therapies and organ availability expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences earnings
-
Rhea-AI Summary
United Therapeutics to present clinical data at the American Thoracic Society 2024 International Conference, including updates on ralinepag and inhaled treprostinil studies. The company will also sponsor the ATS 2024 Women’s Forum and host an educational industry theater on treprostinil induction strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
Rhea-AI Summary
United Therapeutics announces the online availability of a review manuscript on xenotransplantation from genetically-modified pigs to humans, highlighting the progress in organ manufacturing platforms. The company aims to provide transplantable organs to patients with end-stage organ disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
-
Rhea-AI Summary
United Therapeutics (UTHR) announces a $1 billion stock repurchase program, reflecting confidence in its business and future prospects. The company plans to enter an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. The CEO, Martine Rothblatt, highlights the company's strong financial position and potential in revolutionizing organ disease treatment. The ASR agreement will involve an upfront payment of $1 billion to repurchase shares, enhancing long-term shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
buyback
-
Rhea-AI Summary
United Therapeutics Corporation (UTHR) announces an overview and update on operations by EVP at Leerink Partners Global Biopharma Conference 2024. The company emphasizes its vision, mission, and status as a public benefit corporation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
conferences
Rhea-AI Summary
United Therapeutics Corporation (UTHR) announces President and COO's participation in the TD Cowen 44th Annual Health Care Conference. The company's focus on innovation for unmet medical needs and transplantable organs is highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
conferences
-
Rhea-AI Summary
United Therapeutics Corporation (UTHR) reports record revenues of $2.33 billion for full year 2023, marking a 20% growth over 2022. The company achieved solid growth in its commercial business, particularly in the Tyvaso and Remodulin segments. Key financial highlights include a 25% increase in total revenues for the fourth quarter of 2023 compared to the same period in 2022. The company's innovative pipeline and organ manufacturing programs show promising growth potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
-
Rhea-AI Summary
United Therapeutics Corporation initiates litigation against the FDA for allowing Liquidia Corporation to skirt FDA rules in seeking approval for a new drug indication. The lawsuit aims to protect United Therapeutics' patent rights and ensure fair FDA practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
Rhea-AI Summary
United Therapeutics Corporation (UTHR) will announce its Q4 and full-year 2023 financial results on February 21, 2024. The company will host a webcast to discuss the results and highlight its commitment to innovation in the biotech and pharmaceutical sectors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
conferences earnings
United Therapeutics Corp

Nasdaq:UTHR

UTHR Rankings

UTHR Stock Data

10.95B
43.37M
1.72%
97.11%
10.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Silver Spring

About UTHR

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians